247 related articles for article (PubMed ID: 22537934)
1. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
2. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases.
Colombo M; Giarola M; Mariani L; Ripamonti CB; De Benedetti V; Sardella M; Losa M; Manoukian S; Peissel B; Pierotti MA; Pilotti S; Radice P
Mod Pathol; 2008 Oct; 21(10):1262-70. PubMed ID: 18327210
[TBL] [Abstract][Full Text] [Related]
4. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
5. VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.
Saponaro C; Malfettone A; Ranieri G; Danza K; Simone G; Paradiso A; Mangia A
PLoS One; 2013; 8(1):e53070. PubMed ID: 23326384
[TBL] [Abstract][Full Text] [Related]
6. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
[TBL] [Abstract][Full Text] [Related]
7. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
[TBL] [Abstract][Full Text] [Related]
8. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
[TBL] [Abstract][Full Text] [Related]
9. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Eerola H; Heinonen M; Heikkilä P; Kilpivaara O; Tamminen A; Aittomäki K; Blomqvist C; Ristimäki A; Nevanlinna H
Breast Cancer Res; 2008; 10(1):R17. PubMed ID: 18275599
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
13. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
Deb S; Jene N; ; Fox SB
BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
Honrado E; Osorio A; Palacios J; Milne RL; Sánchez L; Díez O; Cazorla A; Syrjakoski K; Huntsman D; Heikkilä P; Lerma E; Kallioniemi A; Rivas C; Foulkes WD; Nevanlinna H; Benítez J
J Clin Oncol; 2005 Oct; 23(30):7503-11. PubMed ID: 16234517
[TBL] [Abstract][Full Text] [Related]
16. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
17. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
[TBL] [Abstract][Full Text] [Related]
18. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
Waddell N; Ten Haaf A; Marsh A; Johnson J; Walker LC; ; Gongora M; Brown M; Grover P; Girolami M; Grimmond S; Chenevix-Trench G; Spurdle AB
PLoS Genet; 2008 May; 4(5):e1000080. PubMed ID: 18497862
[TBL] [Abstract][Full Text] [Related]
20. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
